Yu-Wen Wen

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 11

Top Topics

Neoadjuvant Chemotherapy

Top Venues

PharmacoEconomics

BMC public health

Diagnostics (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Evangelos Tagkalos, Peter Philipp Grimminger, Xing Gao, Chien-Hung Chiu, Eren Uzun, Hauke Lang, Yu-Wen Wen, Yin Kai Chao
Incidence and Predictors of Textbook Outcome after Minimally Invasive Esophagectomy for Cancer: A Two-Center Study. Cancers 16 (6) (2024)
Evangelos Tagkalos, Peter Philipp Grimminger, Xing Gao, Chien-Hung Chiu, Eren Uzun, Hauke Lang, Yu-Wen Wen, Yin Kai Chao
Incidence and Predictors of Textbook Outcome after Minimally Invasive Esophagectomy for Cancer: A Two-Center Study. Cancers 16 (6) (2024)
Chen-Han Chueh, Pei-Kuan Ho, Wai-Hou Li, Ming-Neng Shiu, I-Ting Wang, Yu-Wen Wen, Yi-Wen Tsai
The 2017 Women's Health Initiative study and use of hormone therapy: an emulated repeated cross-sectional study. BMC public health 24 (1) (2024)
Chen-Han Chueh, Pei-Kuan Ho, Wai-Hou Li, Ming-Neng Shiu, I-Ting Wang, Yu-Wen Wen, Yi-Wen Tsai
The 2017 Women's Health Initiative study and use of hormone therapy: an emulated repeated cross-sectional study. BMC public health 24 (1) (2024)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics 41 (3) (2022)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics 41 (3) (2022)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics 41 (3) (2022)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics (2022)
Chen-Han Chueh, Yi-Wen Tsai, Zi-Rong Chen, Ming-Neng Shiu, Yu-Wen Wen, Nai-Jung Chiang
Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy. PharmacoEconomics 41 (3) (2022)
Yi-An Lu, Ming-Shao Tsai, Li-Ang Lee, Shu-Ru Lee, Li-Yun Lin, Chain-Fen Chang, Wan-Ni Lin, Li-Jen Hsin, Chun-Ta Liao, Hsueh-Yu Li, Yu-Wen Wen, Tuan-Jen Fang
Seeking Medical Assistance for Dysphonia Is Associated with an Improved Survival Rate in Laryngeal Cancer: Real-World Evidence. Diagnostics (Basel, Switzerland) 11 (2) (2021)
Chung-Jan Kang, Yu-Wen Wen, Shu-Ru Lee, Li-Yu Lee, Chuen Hsueh, Chien-Yu Lin, Kang-Hsing Fan, Hung-Ming Wang, Chia-Hsun Hsieh, Shu-Hang Ng, Chih-Hua Yeh, Chih-Hung Lin, Chung-Kan Tsao, Tuan-Jen Fang, Shiang-Fu Huang, Li-Ang Lee, Ku-Hao Fang, Tzu-Chen Yen, Nai-Ming Cheng, Tsung-You Tsai, Shiao-Fwu Tai, Chi-Ying Tsai
Surgical Margins Status and Prognosis after Resection of Oral Cavity Squamous Cell Carcinoma: Results from a Taiwanese Nationwide Registry-Based Study. Cancers 14 (1) (2021)